{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:51:48Z","timestamp":1792511508123,"version":"4.5.0"},"reference-count":123,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T00:00:00Z","timestamp":1644192000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T00:00:00Z","timestamp":1644192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s11010-022-04376-6","type":"journal-article","created":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T11:15:54Z","timestamp":1644232554000},"page":"1261-1279","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Transport and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review"],"prefix":"10.1007","volume":"477","author":[{"given":"Veerandra","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonu Kumar","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Villayat","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2395-6086","authenticated-orcid":false,"given":"Malkhey","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,7]]},"reference":[{"key":"4376_CR1","first-page":"8","volume":"76","author":"R Frazer","year":"2007","unstructured":"Frazer R, Irvine AE, McMullin MF (2007) Chronic myeloid leukaemia in the 21st century. Ulster Med J 76:8\u201317","journal-title":"Ulster Med J"},{"key":"4376_CR2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1053\/shem.2003.50034","volume":"40","author":"M Sattlermc","year":"2003","unstructured":"Sattlermc M, Griffin JD (2003) Molecular mechanisms of transformation by the BCR-ABL oncogene. Semin Hematol 40:4\u201310. https:\/\/doi.org\/10.1053\/shem.2003.50034","journal-title":"Semin Hematol"},{"key":"4376_CR3","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/357027","author":"N Iqbal","year":"2014","unstructured":"Iqbal N, Iqbal N (2014) Imatinib: a breakthrough of targeted therapy in cancer. Chemother Res Pract. https:\/\/doi.org\/10.1155\/2014\/357027","journal-title":"Chemother Res Pract"},{"issue":"17","key":"4376_CR4","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1182\/blood-2008-10-183665","volume":"116","author":"DW Sherbenou","year":"2010","unstructured":"Sherbenou DW, Hantschel O, Kaupe I et al (2010) BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib. Blood 116(17):3278\u20133285. https:\/\/doi.org\/10.1182\/blood-2008-10-183665","journal-title":"Blood"},{"key":"4376_CR5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/bs.acr.2018.02.003","volume":"138","author":"SA Rosenzweig","year":"2018","unstructured":"Rosenzweig SA (2018) Acquired resistance to drugs targeting tyrosine kinases. Adv Cancer Res 138:71\u201398","journal-title":"Adv Cancer Res"},{"issue":"4","key":"4376_CR6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.21276\/apjhs.2018.5.4.12","volume":"5","author":"P Singh","year":"2018","unstructured":"Singh P, Gupta SK, Ali V, Verma M (2018) Downregulation of Bcr-Abl oncogene in chronic myeloid leukemia by micro RNAs. Asian Pac J Health Sci 5(4):65\u201384. https:\/\/doi.org\/10.21276\/apjhs.2018.5.4.12","journal-title":"Asian Pac J Health Sci"},{"issue":"9","key":"4376_CR7","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1038\/leu.2015.42","volume":"29","author":"MS Zabriskie","year":"2015","unstructured":"Zabriskie MS, Vellore NA, Gantz KC et al (2015) Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1. Leukemia 29(9):1939\u20131942. https:\/\/doi.org\/10.1038\/leu.2015.42","journal-title":"Leukemia"},{"issue":"8","key":"4376_CR8","doi-asserted-by":"publisher","first-page":"4355","DOI":"10.1182\/blood-2007-09-113175","volume":"111","author":"A Gontarewicz","year":"2008","unstructured":"Gontarewicz A, Balabanov S, Keller G et al (2008) Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. Blood 111(8):4355\u20134364. https:\/\/doi.org\/10.1182\/blood-2007-09-113175","journal-title":"Blood"},{"key":"4376_CR9","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT03459534. Accessed 5 January 2022"},{"issue":"7647","key":"4376_CR10","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/nature21702","volume":"543","author":"AA Wylie","year":"2017","unstructured":"Wylie AA, Schoepfer J, Jahnke W et al (2017) The allosteric inhibitor ABL001 enables dual targeting of BCR\u2013ABL1. Nature 543(7647):733\u2013737. https:\/\/doi.org\/10.1038\/nature21702","journal-title":"Nature"},{"key":"4376_CR11","unstructured":"https:\/\/drugs.ncats.io\/drug\/M3X659D0FY. Accessed 5 January 2022"},{"key":"4376_CR12","unstructured":"https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-asciminib-philadelphia-chromosome-positive-chronic-myeloid-leukemia. Accessed 5 January 2022"},{"issue":"10","key":"4376_CR13","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1089\/omi.2012.0012","volume":"16","author":"SC dos Santos","year":"2012","unstructured":"dos Santos SC, Mira NP, Moreira AS, S\u00e1-Correia I (2012) Quantitative- and phospho-proteomic analysis of the yeast response to the tyrosine kinase inhibitor imatinib to pharmacoproteomics-guided drug line extension. OMICS 16(10):537\u2013551. https:\/\/doi.org\/10.1089\/omi.2012.0012","journal-title":"OMICS"},{"issue":"1","key":"4376_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-12-563","volume":"12","author":"M Khateb","year":"2012","unstructured":"Khateb M, Ruimi N, Khamisie H et al (2012) Overcoming Bcr-Abl T315I mutation by combination of GNF-2 and ATP competitors in an Abl-independent mechanism. BMC Cancer 12(1):1\u201310. https:\/\/doi.org\/10.1186\/1471-2407-12-563","journal-title":"BMC Cancer"},{"issue":"31","key":"4376_CR15","doi-asserted-by":"publisher","first-page":"22158","DOI":"10.18632\/oncotarget.25243","volume":"9","author":"T Meirson","year":"2018","unstructured":"Meirson T, Genna A, Lukic N et al (2018) Targeting invadopodia-mediated breast cancer metastasis by using ABL kinase inhibitors. Oncotarget 9(31):22158. https:\/\/doi.org\/10.18632\/oncotarget.25243","journal-title":"Oncotarget"},{"issue":"7","key":"4376_CR16","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1021\/jm101506n","volume":"54","author":"E Salah","year":"2011","unstructured":"Salah E, Ugochukwu E, Barr AJ et al (2011) Crystal structures of ABL-related gene (ABL2) in complex with imatinib, tozasertib (VX-680), and a Type I inhibitor of the triazole carbothioamide class. J Med Chem 54(7):2359\u20132367. https:\/\/doi.org\/10.1021\/jm101506n","journal-title":"J Med Chem"},{"issue":"12","key":"4376_CR17","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.2165\/00003495-200161120-00007","volume":"61","author":"K Lyseng-Williamson","year":"2001","unstructured":"Lyseng-Williamson K, Jarvis B (2001) Imatinib Drugs 61(12):1765\u20131774. https:\/\/doi.org\/10.2165\/00003495-200161120-00007","journal-title":"Imatinib Drugs"},{"issue":"10","key":"4376_CR18","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1517\/17425255.2010.506873","volume":"6","author":"DR Duckett","year":"2010","unstructured":"Duckett DR, Cameron MD (2010) Metabolism considerations for kinase inhibitors in cancer treatment. Expert Opin Drug Metab Toxicol 6(10):1175\u20131193. https:\/\/doi.org\/10.1517\/17425255.2010.506873","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"4376_CR19","first-page":"139","volume":"295","author":"E Buchdunge","year":"2000","unstructured":"Buchdunge E, Cioffi CL, Law N et al (2000) Abl Protein-Tyrosine Kinase Inhibitor STI571 Inhibits In Vitro Signal Transduction Mediated by c-Kit and Platelet-Derived Growth Factor Receptors. J Pharmacol Exp Ther 295:139\u2013145","journal-title":"J Pharmacol Exp Ther"},{"key":"4376_CR20","first-page":"1a","volume":"20","author":"CD Blanke","year":"2001","unstructured":"Blanke CD (2001) Evaluation of the safety and efficacy of an oral molecularly-targeted therapy, STI571, in patients with unresectable or metastatic gastrointestinal stromal tumors (GISTs) expressing c-kit (CD 117). Proc Am Soc Clin Oncol 20:1a","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"3","key":"4376_CR21","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1124\/pr.55.3.4","volume":"55","author":"MWN Deininger","year":"2003","unstructured":"Deininger MWN, Druker BJ (2003) Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol Rev 55(3):401\u2013423. https:\/\/doi.org\/10.1124\/pr.55.3.4","journal-title":"Pharmacol Rev"},{"issue":"2","key":"4376_CR22","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/84683","volume":"7","author":"P Vigneri","year":"2001","unstructured":"Vigneri P, Wang JYJ (2001) Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR\u2013ABL tyrosine kinase. Nat Med 7(2):228\u2013234. https:\/\/doi.org\/10.1038\/84683","journal-title":"Nat Med"},{"issue":"9","key":"4376_CR23","doi-asserted-by":"publisher","first-page":"879","DOI":"10.2165\/00003088-200544090-00001","volume":"44","author":"B Peng","year":"2005","unstructured":"Peng B, Lloyd P, Schran H (2005) Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 44(9):879\u2013894. https:\/\/doi.org\/10.2165\/00003088-200544090-00001","journal-title":"Clin Pharmacokinet"},{"key":"4376_CR24","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood.V118.21.2745.2745","volume":"118","author":"DL White","year":"2011","unstructured":"White DL, Lu L, Clackson TP et al (2011) ATP dependent efflux transporters ABCB1 and ABCG2 are unlikely to impact the efficacy, or mediate resistance to the tyrosine kinase inhibitor, ponatinib. Blood 118:2745\u20132745. https:\/\/doi.org\/10.1182\/blood.V118.21.2745.2745","journal-title":"Blood"},{"issue":"2\u20133","key":"4376_CR25","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S0925-4439(02)00095-9","volume":"1587","author":"T Heged\u0171s","year":"2002","unstructured":"Heged\u0171s T, \u0150rfi L, Sepr\u0151di A et al (2002) Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. Biochim Biophys Acta Mol Basis Dis 1587(2\u20133):318\u2013325. https:\/\/doi.org\/10.1016\/S0925-4439(02)00095-9","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"10","key":"4376_CR26","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1158\/1078-0432.CCR-07-4913","volume":"14","author":"S Hu","year":"2008","unstructured":"Hu S, Franke RM, Filipski KK et al (2008) Interaction of imatinib with human organic ion carriers. Clin Cancer Res 14(10):3141\u20133148. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-4913","journal-title":"Clin Cancer Res"},{"issue":"2","key":"4376_CR27","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/sj.leu.2404897","volume":"22","author":"S Shukla","year":"2008","unstructured":"Shukla S, Sauna ZE, Ambudkar S (2008) Evidence for the interaction of imatinib at the transport-substrate site(s) of the multidrug-resistance-linked ABC drug transporters ABCB1 (P-glycoprotein) and ABCG2. Leukemia 22(2):445\u2013447. https:\/\/doi.org\/10.1038\/sj.leu.2404897","journal-title":"Leukemia"},{"issue":"8","key":"4376_CR28","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1124\/dmd.109.031302","volume":"38","author":"M Dohse","year":"2010","unstructured":"Dohse M, Scharenberg C, Shukla S et al (2010) Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos 38(8):1371\u20131380. https:\/\/doi.org\/10.1124\/dmd.109.031302","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"4376_CR29","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1182\/blood-2004-04-1398","volume":"104","author":"H Burger","year":"2004","unstructured":"Burger H, van Tol H, Boersma AWM et al (2004) Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)\/ABCG2 drug pump. Blood 104(9):2940\u20132942. https:\/\/doi.org\/10.1182\/blood-2004-04-1398","journal-title":"Blood"},{"key":"4376_CR30","unstructured":"Giacomini KM (2005) Membrane transporters and drug response. Goodman & Gilman\u2019s The Pharmacological Basis of Therapeutics 41\u201370"},{"issue":"8","key":"4376_CR31","first-page":"3458","volume":"61","author":"M Maliepaard","year":"2001","unstructured":"Maliepaard M, Scheffer GL, Faneyte IF et al (2001) Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 61(8):3458\u20133464","journal-title":"Cancer Res"},{"key":"4376_CR32","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0143-4004(03)00170-X","volume":"24","author":"M Nagashige","year":"2003","unstructured":"Nagashige M, Ushigome F, Koyabu N et al (2003) Basal membrane localization of MRP1 in human placental trophoblast. Placenta 24:951\u2013958. https:\/\/doi.org\/10.1016\/S0143-4004(03)00170-X","journal-title":"Placenta"},{"issue":"3","key":"4376_CR33","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1158\/1078-0432.CCR-10-2250","volume":"17","author":"K Eechoute","year":"2011","unstructured":"Eechoute K, Sparreboom A, Burger H et al (2011) Drug transporters and imatinib treatment: implications for clinical practice. Clin Cancer Res 17(3):406\u2013415. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-2250","journal-title":"Clin Cancer Res"},{"issue":"2","key":"4376_CR34","doi-asserted-by":"publisher","first-page":"448","DOI":"10.4081\/oncol.2020.448","volume":"14","author":"SK Gupta","year":"2020","unstructured":"Gupta SK, Singh P, Ali V, Verma M (2020) Role of membrane-embedded drug efflux ABC transporters in the cancer chemotherapy. Oncol Rev 14(2):448. https:\/\/doi.org\/10.4081\/oncol.2020.448","journal-title":"Oncol Rev"},{"issue":"5","key":"4376_CR35","doi-asserted-by":"publisher","first-page":"470","DOI":"10.2174\/138920009788897975","volume":"10","author":"J Hartmann","year":"2009","unstructured":"Hartmann J, Haap M, Kopp H-G, Lipp H-P (2009) Tyrosine kinase inhibitors \u2013 a review on pharmacology, metabolism and side effects. Curr Drug Metab 10(5):470\u2013481. https:\/\/doi.org\/10.2174\/138920009788897975","journal-title":"Curr Drug Metab"},{"issue":"7","key":"4376_CR36","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1592\/phco.26.7.903","volume":"26","author":"JH Beumer","year":"2006","unstructured":"Beumer JH, Natale JJ, Lagattuta TF et al (2006) Disposition of imatinib and its metabolite CGP74588 in a patient with chronic myelogenous leukemia and short-bowel syndrome. Pharmacotherapy 26(7):903\u2013907. https:\/\/doi.org\/10.1592\/phco.26.7.903","journal-title":"Pharmacotherapy"},{"issue":"02","key":"4376_CR37","doi-asserted-by":"publisher","first-page":"4395","DOI":"10.2217\/fon-2019-0555","volume":"16","author":"C Gambacorti-Passerini","year":"2020","unstructured":"Gambacorti-Passerini C, le Coutre P, Piazza R (2020) The role of bosutinib in the treatment of chronic myeloid leukemia. Future Oncol 16(02):4395\u20134408. https:\/\/doi.org\/10.2217\/fon-2019-0555","journal-title":"Future Oncol"},{"issue":"4","key":"4376_CR38","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s00280-004-0832-z","volume":"54","author":"C Dutreix","year":"2004","unstructured":"Dutreix C, Peng B, Mehring G et al (2004) Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects. Cancer Chemother Pharmacol 54(4):290\u2013294. https:\/\/doi.org\/10.1007\/s00280-004-0832-z","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"4376_CR39","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2165\/00003088-200544040-00002","volume":"44","author":"B Rochat","year":"2005","unstructured":"Rochat B (2005) Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance. Clin Pharmacokinet 44(4):349\u2013366. https:\/\/doi.org\/10.2165\/00003088-200544040-00002","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"4376_CR40","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1124\/dmd.105.004283","volume":"33","author":"H-P Gschwind","year":"2005","unstructured":"Gschwind H-P, Pfaar U, Waldmeier F et al (2005) metabolism and disposition of imatinib mesylate in healthy volunteers. Drug Metab Dispos 33(10):1503\u20131512. https:\/\/doi.org\/10.1124\/dmd.105.004283","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"4376_CR41","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1111\/j.1476-5381.2010.00946.x","volume":"161","author":"N Nebot","year":"2010","unstructured":"Nebot N, Crettol S, D\u2019Esposito F et al (2010) Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes. Br J Pharmacol 161(5):1059\u20131069. https:\/\/doi.org\/10.1111\/j.1476-5381.2010.00946.x","journal-title":"Br J Pharmacol"},{"issue":"3","key":"4376_CR42","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/jms.1002","volume":"41","author":"M Marull","year":"2006","unstructured":"Marull M, Rochat B (2006) Fragmentation study of imatinib and characterization of new imatinib metabolites by liquid chromatography\u2013triple-quadrupole and linear ion trap mass spectrometers. J Mass Spectrom 41(3):390\u2013404. https:\/\/doi.org\/10.1002\/jms.1002","journal-title":"J Mass Spectrom"},{"issue":"9","key":"4376_CR43","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1002\/cncr.21834","volume":"106","author":"K Wyman","year":"2006","unstructured":"Wyman K, Atkins MB, Prieto V et al (2006) Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma. Cancer 106(9):2005\u20132011. https:\/\/doi.org\/10.1002\/cncr.21834","journal-title":"Cancer"},{"issue":"10","key":"4376_CR44","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1038\/sj.leu.2402702","volume":"16","author":"K Ohyashiki","year":"2002","unstructured":"Ohyashiki K, Kuriyama Y, Nakajima A et al (2002) Imatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis. Leukemia 16(10):2160\u20132161. https:\/\/doi.org\/10.1038\/sj.leu.2402702","journal-title":"Leukemia"},{"issue":"3","key":"4376_CR45","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1007\/s12032-009-9284-y","volume":"27","author":"O Tonyali","year":"2010","unstructured":"Tonyali O, Coskun U, Yildiz R et al (2010) Imatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumors. Med Oncol 27(3):768\u2013773. https:\/\/doi.org\/10.1007\/s12032-009-9284-y","journal-title":"Med Oncol"},{"issue":"10","key":"4376_CR46","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1038\/sj.bjc.6601152","volume":"89","author":"SG O\u2019Brien","year":"2003","unstructured":"O\u2019Brien SG, Meinhardt P, Bond E et al (2003) Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome P450 3A4 substrate, in patients with chronic myeloid leukaemia. Br J Cancer 89(10):1855\u20131859. https:\/\/doi.org\/10.1038\/sj.bjc.6601152","journal-title":"Br J Cancer"},{"key":"4376_CR47","doi-asserted-by":"publisher","DOI":"10.2165\/00128415-200208920-00026","author":"MA Elliott","year":"2002","unstructured":"Elliott MA (2002) Imatinib mesylate. Reactions Weekly. https:\/\/doi.org\/10.2165\/00128415-200208920-00026","journal-title":"Reactions Weekly"},{"issue":"6","key":"4376_CR48","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1101\/gad.1052503","volume":"17","author":"J Brennan","year":"2003","unstructured":"Brennan J (2003) Pdgfr-alpha mediates testis cord organization and fetal Leydig cell development in the XY gonad. Genes Dev 17(6):800\u2013810. https:\/\/doi.org\/10.1101\/gad.1052503","journal-title":"Genes Dev"},{"issue":"2","key":"4376_CR49","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1095\/biolreprod64.2.451","volume":"64","author":"CTF Huang","year":"2001","unstructured":"Huang CTF, Weitsman SR, Dykes BN, Magoffin DA (2001) Stem cell factor and insulin-like growth factor-I stimulate luteinizing hormone-independent differentiation of rat ovarian theca cells. Biol Reprod 64(2):451\u2013456. https:\/\/doi.org\/10.1095\/biolreprod64.2.451","journal-title":"Biol Reprod"},{"issue":"4","key":"4376_CR50","doi-asserted-by":"publisher","first-page":"389","DOI":"10.4103\/0253-7613.83107","volume":"43","author":"K Bairy","year":"2011","unstructured":"Bairy K, Ramnarayan K, Prasad A, Nalini K (2011) Effect of imatinib on the biochemical parameters of the reproductive function in male Swiss albino mice. Indian J Pharmacol 43(4):389. https:\/\/doi.org\/10.4103\/0253-7613.83107","journal-title":"Indian J Pharmacol"},{"issue":"2","key":"4376_CR51","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1093\/annonc\/mdh068","volume":"15","author":"B Arora","year":"2004","unstructured":"Arora B, Kumar L, Sharma A et al (2004) Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate. Ann Oncol 15(2):358\u2013359. https:\/\/doi.org\/10.1093\/annonc\/mdh068","journal-title":"Ann Oncol"},{"issue":"11","key":"4376_CR52","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1002\/cncr.11812","volume":"98","author":"AS Tsao","year":"2003","unstructured":"Tsao AS, Kantarjian H, Cortes J et al (2003) Imatinib mesylate causes hypopigmentation in the skin. Cancer 98(11):2483\u20132487. https:\/\/doi.org\/10.1002\/cncr.11812","journal-title":"Cancer"},{"key":"4376_CR53","first-page":"162","volume":"12","author":"N Valizadeh","year":"2011","unstructured":"Valizadeh N (2011) Imatinib induced facial skin hyperpigmentation in a case of chronic myelogenous leukemia. Shiraz E Med J 12:162\u2013164","journal-title":"Shiraz E Med J"},{"issue":"1","key":"4376_CR54","doi-asserted-by":"publisher","first-page":"94","DOI":"10.22543\/7674.71.P9499","volume":"7","author":"O Orasan","year":"2020","unstructured":"Orasan O, Stefan A, Minciuna I et al (2020) Imatinib-induced interstitial pneumonitis \u2013 a literature review and case report. J Mind Med Sci 7(1):94\u201399. https:\/\/doi.org\/10.22543\/7674.71.P9499","journal-title":"J Mind Med Sci"},{"issue":"22","key":"4376_CR55","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1182\/blood.V114.22.1126.1126","volume":"114","author":"M Deininger","year":"2009","unstructured":"Deininger M, O\u2019Brien SG, Guilhot F et al (2009) International randomized study of interferon Vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 114(22):1126. https:\/\/doi.org\/10.1182\/blood.V114.22.1126.1126","journal-title":"Blood"},{"key":"4376_CR56","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/nrc2126","volume":"7","author":"E Weisberg","year":"2007","unstructured":"Weisberg E, Manley PW, Cowan-Jacob SW et al (2007) Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 7:345\u2013356. https:\/\/doi.org\/10.1038\/nrc2126","journal-title":"Nat Rev Cancer"},{"key":"4376_CR57","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim D-W, Issaragrisil S et al (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362:2251\u20132259. https:\/\/doi.org\/10.1056\/NEJMoa0912614","journal-title":"N Engl J Med"},{"issue":"4","key":"4376_CR58","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1111\/j.1476-5381.2009.00383.x","volume":"158","author":"C Heged\u0171s","year":"2009","unstructured":"Heged\u0171s C, \u00d6zvegy-Laczka C, Ap\u00e1ti \u00c1 et al (2009) Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol 158(4):1153\u20131164. https:\/\/doi.org\/10.1111\/j.1476-5381.2009.00383.x","journal-title":"Br J Pharmacol"},{"issue":"5","key":"4376_CR59","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/nrc2126","volume":"7","author":"E Weisberg","year":"2007","unstructured":"Weisberg E, Manley PW, Cowan-Jacob SW et al (2007) Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 7(5):345\u2013356. https:\/\/doi.org\/10.1038\/nrc2126","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"4376_CR60","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","volume":"104","author":"J Thomas","year":"2004","unstructured":"Thomas J, Wang L, Clark RE, Pirmohamed M (2004) Active transport of imatinib into and out of cells: implications for drug resistance. Blood 104(12):3739\u20133745. https:\/\/doi.org\/10.1182\/blood-2003-12-4276","journal-title":"Blood"},{"issue":"1","key":"4376_CR61","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1159\/000091943","volume":"77","author":"H Prenen","year":"2006","unstructured":"Prenen H, Guetens G, de Boeck G et al (2006) Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell lines. Pharmacology 77(1):11\u201316. https:\/\/doi.org\/10.1159\/000091943","journal-title":"Pharmacology"},{"issue":"3","key":"4376_CR62","doi-asserted-by":"publisher","first-page":"569","DOI":"10.3109\/10428194.2012.715345","volume":"54","author":"LN Eadie","year":"2013","unstructured":"Eadie LN, Saunders VA, Hughes TP, White DL (2013) Degree of kinase inhibition achieved in vitro by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2. Leuk Lymphoma 54(3):569\u2013578. https:\/\/doi.org\/10.3109\/10428194.2012.715345","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"4376_CR63","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0192180","volume":"13","author":"LN Eadie","year":"2018","unstructured":"Eadie LN, Dang P, Goyne JM et al (2018) ABCC6 plays a significant role in the transport of nilotinib and dasatinib, and contributes to TKI resistance in vitro, in both cell lines and primary patient mononuclear cells. PLoS ONE 13(1):e0192180. https:\/\/doi.org\/10.1371\/journal.pone.0192180","journal-title":"PLoS ONE"},{"issue":"6","key":"4376_CR64","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1038\/sj.leu.2404638","volume":"21","author":"C Brendel","year":"2007","unstructured":"Brendel C, Scharenberg C, Dohse M et al (2007) Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia 21(6):1267\u20131275. https:\/\/doi.org\/10.1038\/sj.leu.2404638","journal-title":"Leukemia"},{"key":"4376_CR65","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1016\/j.clinthera.2009.11.015","volume":"31","author":"OQP Yin","year":"2009","unstructured":"Yin OQP, Gallagher N, Tanaka C et al (2009) Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study. Clin Ther 31:2459\u20132469. https:\/\/doi.org\/10.1016\/j.clinthera.2009.11.015","journal-title":"Clin Ther"},{"issue":"17","key":"4376_CR66","doi-asserted-by":"publisher","first-page":"5325","DOI":"10.1158\/1078-0432.CCR-08-0308","volume":"14","author":"M Hazarika","year":"2008","unstructured":"Hazarika M, Jiang X, Liu Q et al (2008) Tasigna for chronic and accelerated phase philadelphia chromosome-positive chronic myelogenous leukemia resistant to or intolerant of imatinib. Clin Cancer Res 14(17):5325\u20135331. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-0308","journal-title":"Clin Cancer Res"},{"issue":"9","key":"4376_CR67","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/nrd2135","volume":"5","author":"H Kantarjian","year":"2006","unstructured":"Kantarjian H, Jabbour E, Grimley J, Kirkpatrick P (2006) Dasatinib. Nat Rev Drug Discov 5(9):717\u2013719. https:\/\/doi.org\/10.1038\/nrd2135","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"4376_CR68","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2165\/00063030-200822010-00007","volume":"22","author":"SJ Keam","year":"2008","unstructured":"Keam SJ (2008) Dasatinib BioDrugs 22(1):59\u201369. https:\/\/doi.org\/10.2165\/00063030-200822010-00007","journal-title":"Dasatinib BioDrugs"},{"issue":"13","key":"4376_CR69","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.2165\/11207580-000000000-00000","volume":"71","author":"PL McCormack","year":"2011","unstructured":"McCormack PL, Keam SJ (2011) Dasatinib Drugs 71(13):1771\u20131795. https:\/\/doi.org\/10.2165\/11207580-000000000-00000","journal-title":"Dasatinib Drugs"},{"issue":"3","key":"4376_CR70","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2165\/11535870-000000000-00000","volume":"24","author":"F Condorelli","year":"2010","unstructured":"Condorelli F, Genazzani AA (2010) Dasatinib BioDrugs 24(3):157\u2013163. https:\/\/doi.org\/10.2165\/11535870-000000000-00000","journal-title":"Dasatinib BioDrugs"},{"issue":"8","key":"4376_CR71","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1002\/cncr.31232","volume":"124","author":"M Talpaz","year":"2018","unstructured":"Talpaz M, Saglio G, Atallah E, Rousselot P (2018) Dasatinib dose management for the treatment of chronic myeloid leukemia. Cancer 124(8):1660\u20131672. https:\/\/doi.org\/10.1002\/cncr.31232","journal-title":"Cancer"},{"issue":"14","key":"4376_CR72","doi-asserted-by":"publisher","first-page":"4878","DOI":"10.3390\/ijms21144878","volume":"21","author":"L Piscitani","year":"2020","unstructured":"Piscitani L, Sirolli V, di Liberato L et al (2020) Nephrotoxicity associated with novel anticancer agents (Aflibercept, Dasatinib, Nivolumab): case series and nephrological considerations. Int J Mol Sci 21(14):4878. https:\/\/doi.org\/10.3390\/ijms21144878","journal-title":"Int J Mol Sci"},{"issue":"4","key":"4376_CR73","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","volume":"37","author":"TP Braun","year":"2020","unstructured":"Braun TP, Eide CA, Druker BJ (2020) Response and resistance to BCR-ABL1-targeted therapies. Cancer Cell 37(4):530\u2013542. https:\/\/doi.org\/10.1016\/j.ccell.2020.03.006","journal-title":"Cancer Cell"},{"key":"4376_CR74","doi-asserted-by":"publisher","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","volume":"65","author":"T O\u2019Hare","year":"2005","unstructured":"O\u2019Hare T, Walters DK, Stoffregen EP et al (2005) In vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 65:4500\u20134505. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-0259","journal-title":"Cancer Res"},{"issue":"25","key":"4376_CR75","doi-asserted-by":"publisher","first-page":"4204","DOI":"10.1200\/JCO.2009.21.8230","volume":"27","author":"T Hughes","year":"2009","unstructured":"Hughes T, Saglio G, Branford S et al (2009) Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol 27(25):4204. https:\/\/doi.org\/10.1200\/JCO.2009.21.8230","journal-title":"J Clin Oncol"},{"issue":"12","key":"4376_CR76","doi-asserted-by":"publisher","first-page":"3881","DOI":"10.1158\/1078-0432.CCR-07-5095","volume":"14","author":"DK Hiwase","year":"2008","unstructured":"Hiwase DK, Saunders V, Hewett D et al (2008) Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clin Cancer Res 14(12):3881\u20133888. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-5095","journal-title":"Clin Cancer Res"},{"key":"4376_CR77","doi-asserted-by":"publisher","first-page":"4359","DOI":"10.1158\/1078-0432.CCR-13-0980","volume":"19","author":"BD Furmanski","year":"2013","unstructured":"Furmanski BD, Hu S, Fujita K et al (2013) Contribution of Abcc4-mediated gastric transport to the absorption and efficacy of dasatinib. Clin Cancer Res 19:4359\u20134370. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-0980","journal-title":"Clin Cancer Res"},{"issue":"6","key":"4376_CR78","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1177\/0091270009333854","volume":"49","author":"T Eley","year":"2009","unstructured":"Eley T, Luo FR, Agrawal S et al (2009) Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects. J Clin Pharmacol 49(6):700\u2013709. https:\/\/doi.org\/10.1177\/0091270009333854","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"4376_CR79","first-page":"183","volume":"46","author":"J Fallingborg","year":"1999","unstructured":"Fallingborg J (1999) Intraluminal pH of the human gastrointestinal tract. Dan Med Bull 46(3):183\u2013196","journal-title":"Dan Med Bull"},{"key":"4376_CR80","doi-asserted-by":"publisher","unstructured":"Lindauer M, Hochhaus A (2010) Dasatinib. In: Martens U. (eds) Small molecules in oncology. Recent results in cancer research vol 184 pp.83\u2013102. Springer Berlin Heidelberg. https:\/\/doi.org\/10.1007\/978-3-642-01222-8_7","DOI":"10.1007\/978-3-642-01222-8_7"},{"issue":"7","key":"4376_CR81","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1124\/dmd.107.018267","volume":"36","author":"LJ Christopher","year":"2008","unstructured":"Christopher LJ, Cui D, Wu C et al (2008) Metabolism and disposition of dasatinib after oral administration to humans. Drug Metab Dispos 36(7):1357\u20131364. https:\/\/doi.org\/10.1124\/dmd.107.018267","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"4376_CR82","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s40272-018-0319-8","volume":"20","author":"EH McCafferty","year":"2018","unstructured":"McCafferty EH, Dhillon S, Deeks ED (2018) Dasatinib: a review in pediatric chronic myeloid leukemia. Paediatr Drugs 20(6):593\u2013600. https:\/\/doi.org\/10.1007\/s40272-018-0319-8","journal-title":"Paediatr Drugs"},{"issue":"3","key":"4376_CR83","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.taap.2012.04.010","volume":"261","author":"T Xue","year":"2012","unstructured":"Xue T, Luo P, Zhu H et al (2012) Oxidative stress is involved in Dasatinib-induced apoptosis in rat primary hepatocytes. Toxicol Appl Pharmacol 261(3):280\u2013291. https:\/\/doi.org\/10.1016\/j.taap.2012.04.010","journal-title":"Toxicol Appl Pharmacol"},{"issue":"1","key":"4376_CR84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-018-0685-2","volume":"11","author":"JE Cortes","year":"2018","unstructured":"Cortes JE, Apperley JF, DeAngelo DJ et al (2018) Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review. J Hematol Oncol 11(1):1\u201312. https:\/\/doi.org\/10.1186\/s13045-018-0685-2","journal-title":"J Hematol Oncol"},{"issue":"12","key":"4376_CR85","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1177\/0091270010387427","volume":"51","author":"R Abbas","year":"2011","unstructured":"Abbas R, Hug BA, Leister C et al (2011) Effect of ketoconazole on the pharmacokinetics of oral bosutinib in healthy subjects. J Clin Pharmacol 51(12):1721\u20131727. https:\/\/doi.org\/10.1177\/0091270010387427","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"4376_CR86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-015-0179-4","volume":"8","author":"S Redaelli","year":"2015","unstructured":"Redaelli S, Perini P, Ceccon M et al (2015) In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib. J Hematol Oncol 8(1):1\u201310. https:\/\/doi.org\/10.1186\/s13045-015-0179-4","journal-title":"J Hematol Oncol"},{"issue":"10","key":"4376_CR87","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s40262-016-0391-6","volume":"55","author":"R Abbas","year":"2016","unstructured":"Abbas R, Hsyu P-H (2016) Clinical pharmacokinetics and pharmacodynamics of bosutinib. Clin Pharmacokinet 55(10):1191\u20131204. https:\/\/doi.org\/10.1007\/s40262-016-0391-6","journal-title":"Clin Pharmacokinet"},{"key":"4376_CR88","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.DMPK-13-RG-126","author":"P-H Hsyu","year":"2014","unstructured":"Hsyu P-H, Mould DR, Abbas R, Amantea M (2014) Population Pharmacokinetic and Pharmacodynamic Analysis of Bosutinib. Drug Metab Pharmacokinet DMPK. https:\/\/doi.org\/10.2133\/dmpk.DMPK-13-RG-126","journal-title":"Drug Metab Pharmacokinet DMPK"},{"issue":"1","key":"4376_CR89","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1515\/dmdi-2014-0026","volume":"30","author":"R Abbas","year":"2015","unstructured":"Abbas R, Boni J, Sonnichsen D (2015) Effect of rifampin on the pharmacokinetics of bosutinib, a dual Src\/Abl tyrosine kinase inhibitor, when administered concomitantly to healthy subjects. Drug Metab Pers Ther 30(1):57\u201363. https:\/\/doi.org\/10.1515\/dmdi-2014-0026","journal-title":"Drug Metab Pers Ther"},{"key":"4376_CR90","doi-asserted-by":"publisher","first-page":"134","DOI":"10.15344\/2456-3501\/2018\/134","volume":"3","author":"J Perea","year":"2018","unstructured":"Perea J, Rada B, Gand\u00eda N (2018) Comparative pharmacology of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia. Int. J. Clin. Pharmacol. Pharmacother 3:134. https:\/\/doi.org\/10.15344\/2456-3501\/2018\/134","journal-title":"Int. J. Clin. Pharmacol. Pharmacother"},{"issue":"8","key":"4376_CR91","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s40261-013-0103-z","volume":"33","author":"R Abbas","year":"2013","unstructured":"Abbas R, Leister C, Sonnichsen D (2013) A clinical study to examine the potential effect of lansoprazole on the pharmacokinetics of bosutinib when administered concomitantly to healthy subjects. Clin Drug Investig 33(8):589\u2013595. https:\/\/doi.org\/10.1007\/s40261-013-0103-z","journal-title":"Clin Drug Investig"},{"issue":"17","key":"4376_CR92","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.1182\/blood-2011-05-355594","volume":"118","author":"JE Cortes","year":"2011","unstructured":"Cortes JE, Kantarjian HM, Br\u00fcmmendorf TH et al (2011) Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome\u2013positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood 118(17):4567\u20134576. https:\/\/doi.org\/10.1182\/blood-2011-05-355594","journal-title":"Blood"},{"issue":"10","key":"4376_CR93","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1002\/ajh.23788","volume":"89","author":"C Gambacorti-Passerini","year":"2014","unstructured":"Gambacorti-Passerini C, Cortes JE, Lipton JH et al (2014) Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia. Am J Hematol 89(10):947\u2013953. https:\/\/doi.org\/10.1002\/ajh.23788","journal-title":"Am J Hematol"},{"issue":"15","key":"4376_CR94","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.1182\/blood-2011-11-390120","volume":"119","author":"HJ Khoury","year":"2012","unstructured":"Khoury HJ, Cortes JE, Kantarjian HM et al (2012) Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and\/or nilotinib therapy failure. Blood 119(15):3403\u20133412. https:\/\/doi.org\/10.1182\/blood-2011-11-390120","journal-title":"Blood"},{"key":"4376_CR95","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2147\/OTT.S19901","volume":"6","author":"S Koschmieder","year":"2013","unstructured":"Koschmieder S (2013) Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemia. Onco Targets Ther 6:99\u2013106. https:\/\/doi.org\/10.2147\/OTT.S19901","journal-title":"Onco Targets Ther"},{"issue":"6","key":"4376_CR96","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/ajh.24360","volume":"91","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Jean Khoury H, Kantarjian H et al (2016) Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib. Am J Hematol 91(6):606\u2013616. https:\/\/doi.org\/10.1002\/ajh.24360","journal-title":"Am J Hematol"},{"key":"4376_CR97","doi-asserted-by":"publisher","first-page":"243","DOI":"10.2147\/BTT.S50734","volume":"8","author":"C Lim","year":"2014","unstructured":"Lim C, Miller GD, Bruno BJ (2014) Resistant mutations in CML and Ph+ALL – role of ponatinib. Biol Targets Ther 8:243. https:\/\/doi.org\/10.2147\/BTT.S50734","journal-title":"Biol Targets Ther"},{"issue":"22","key":"4376_CR98","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1056\/NEJMOA1205127","volume":"367","author":"JE Cortes","year":"2012","unstructured":"Cortes JE, Kantarjian H, Shah NP et al (2012) Ponatinib in refractory philadelphia chromosome-positive leukemias. N Engl J Med 367(22):2075\u20132088. https:\/\/doi.org\/10.1056\/NEJMOA1205127","journal-title":"N Engl J Med"},{"issue":"5","key":"4376_CR99","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/J.CCR.2009.09.028","volume":"16","author":"T O\u2019Hare","year":"2009","unstructured":"O\u2019Hare T, Shakespeare WC, Zhu X et al (2009) AP24534, a Pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16(5):401\u2013412. https:\/\/doi.org\/10.1016\/J.CCR.2009.09.028","journal-title":"Cancer Cell"},{"key":"4376_CR100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1747-0285.2010.01054.x","volume":"77","author":"T Zhou","year":"2011","unstructured":"Zhou T, Commodore L, Huang W-S et al (2011) Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance. Chem Biol Drug Des 77:1. https:\/\/doi.org\/10.1111\/j.1747-0285.2010.01054.x","journal-title":"Chem Biol Drug Des"},{"issue":"9","key":"4376_CR101","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1158\/1535-7163.MCT-12-0302","volume":"11","author":"R Sen","year":"2012","unstructured":"Sen R, Natarajan K, Bhullar J et al (2012) The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2. Mol Cancer Ther 11(9):2033\u20132044. https:\/\/doi.org\/10.1158\/1535-7163.MCT-12-0302","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"4376_CR102","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1038\/leu.2015.35","volume":"29","author":"L Lu","year":"2015","unstructured":"Lu L, Saunders VA, Leclercq TM et al (2015) Ponatinib is not transported by ABCB1, ABCG2 or OCT-1 in CML cells. Leukemia 29(8):1792\u20131794. https:\/\/doi.org\/10.1038\/leu.2015.35","journal-title":"Leukemia"},{"issue":"2","key":"4376_CR103","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1124\/jpet.117.246116","volume":"365","author":"JK Laramy","year":"2018","unstructured":"Laramy JK, Kim M, Parrish KE et al (2018) Pharmacokinetic assessment of cooperative efflux of the multitargeted kinase inhibitor ponatinib across the blood-brain barrier. J Pharmacol Exp Ther 365(2):249\u2013261. https:\/\/doi.org\/10.1124\/jpet.117.246116","journal-title":"J Pharmacol Exp Ther"},{"issue":"24","key":"4376_CR104","doi-asserted-by":"publisher","first-page":"6457","DOI":"10.1158\/0008-5472.CAN-12-1340","volume":"72","author":"E Malofeeva","year":"2012","unstructured":"Malofeeva E, v., Domanitskaya N, Gudima M, Hopper-Borge EA, (2012) Modulation of the ATPase and transport activities of broad-acting multidrug resistance factor ABCC10 (MRP7). Cancer Res 72(24):6457\u20136467. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-1340","journal-title":"Cancer Res"},{"issue":"10","key":"4376_CR105","doi-asserted-by":"publisher","first-page":"3649","DOI":"10.1158\/0008-5472.CAN-10-3623","volume":"71","author":"EA Hopper-Borge","year":"2011","unstructured":"Hopper-Borge EA, Churchill T, Paulose C et al (2011) Contribution of Abcc10 (Mrp7) to in vivo paclitaxel resistance as assessed in Abcc10 \u2212\/\u2212 Mice. Cancer Res 71(10):3649\u20133657. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-3623","journal-title":"Cancer Res"},{"issue":"4","key":"4376_CR106","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.3892\/or.2014.3002","volume":"31","author":"YL Sun","year":"2014","unstructured":"Sun YL, Kumar P, Sodani K et al (2014) Ponatinib enhances anticancer drug sensitivity in MRP7-overexpressing cells. Oncol Rep 31(4):1605\u20131612. https:\/\/doi.org\/10.3892\/or.2014.3002","journal-title":"Oncol Rep"},{"issue":"21","key":"4376_CR107","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1182\/blood.V120.21.163.163","volume":"120","author":"JE Cortes","year":"2012","unstructured":"Cortes JE, Kim D-W, Pinilla-Ibarz J et al (2012) A pivotal phase 2 trial of ponatinib in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial. Blood 120(21):163. https:\/\/doi.org\/10.1182\/blood.V120.21.163.163","journal-title":"Blood"},{"issue":"2","key":"4376_CR108","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s00280-014-2511-z","volume":"74","author":"NI Narasimhan","year":"2014","unstructured":"Narasimhan NI, Dorer DJ, Davis J et al (2014) Evaluation of pharmacokinetics and safety of ponatinib in subjects with chronic hepatic impairment and matched healthy subjects. Cancer Chemother Pharmacol 74(2):341\u2013348. https:\/\/doi.org\/10.1007\/s00280-014-2511-z","journal-title":"Cancer Chemother Pharmacol"},{"issue":"17","key":"4376_CR109","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1056\/NEJMoa1306494","volume":"351","author":"JE Cortes","year":"2013","unstructured":"Cortes JE, Kim D-W, Pinilla-Ibarz J et al (2013) A phase 2 Trial of ponatinib in philadelphia chromosome-positive leukemias. N Engl J Med 351(17):1721\u20131730. https:\/\/doi.org\/10.1056\/NEJMoa1306494","journal-title":"N Engl J Med"},{"key":"4376_CR110","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1124\/jpet.117.243246","volume":"363","author":"D Lin","year":"2017","unstructured":"Lin D, Kostov R, Huang JT-J et al (2017) Novel pathways of ponatinib disposition catalyzed by CYP1A1 involving generation of potentially toxic metabolites. J Pharmacol Exp Ther 363:12\u201319. https:\/\/doi.org\/10.1124\/jpet.117.243246","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"4376_CR111","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s00280-017-3240-x","volume":"79","author":"YE Ye","year":"2017","unstructured":"Ye YE, Woodward CN, Narasimhan NI (2017) Absorption, metabolism, and excretion of [14C] ponatinib after a single oral dose in humans. Cancer Chemother Pharmacol 79(3):507\u2013518. https:\/\/doi.org\/10.1007\/s00280-017-3240-x","journal-title":"Cancer Chemother Pharmacol"},{"issue":"76","key":"4376_CR112","doi-asserted-by":"publisher","first-page":"72575","DOI":"10.1039\/C6RA09985H","volume":"6","author":"AA Kadi","year":"2016","unstructured":"Kadi AA, Darwish HW, Attwa MW, Amer SM (2016) Detection and characterization of ponatinib reactive metabolites by liquid chromatography tandem mass spectrometry and elucidation of bioactivation pathways. RSC Adv 6(76):72575\u201372585. https:\/\/doi.org\/10.1039\/C6RA09985H","journal-title":"RSC Adv"},{"issue":"8","key":"4376_CR113","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1634\/theoncologist.2015-0253","volume":"20","author":"JF Gainor","year":"2015","unstructured":"Gainor JF, Chabner BA (2015) Ponatinib: accelerated disapproval. Oncologist 20(8):847. https:\/\/doi.org\/10.1634\/theoncologist.2015-0253","journal-title":"Oncologist"},{"issue":"1","key":"4376_CR114","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1476-4598-9-75","volume":"9","author":"JR Sierra","year":"2010","unstructured":"Sierra JR, Cepero V, Giordano S (2010) Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. Mol Cancer 9(1):1\u201313. https:\/\/doi.org\/10.1186\/1476-4598-9-75","journal-title":"Mol Cancer"},{"issue":"5","key":"4376_CR115","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1007\/s00280-013-2131-z","volume":"71","author":"JM Gozgit","year":"2013","unstructured":"Gozgit JM, Squillace RM, Wongchenko MJ et al (2013) Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models. Cancer Chemother Pharmacol 71(5):1315\u20132132. https:\/\/doi.org\/10.1007\/s00280-013-2131-z","journal-title":"Cancer Chemother Pharmacol"},{"issue":"12","key":"4376_CR116","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM et al (2016) Final 5-year study results of dasision: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial. J Clin Oncol 34(12):1402. https:\/\/doi.org\/10.1200\/JCO.2015.64.8899","journal-title":"J Clin Oncol"},{"issue":"24","key":"4376_CR117","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","volume":"381","author":"TP Hughes","year":"2019","unstructured":"Hughes TP, Mauro MJ, Cortes JE et al (2019) Asciminib in chronic Myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med 381(24):2315\u20132326. https:\/\/doi.org\/10.1056\/NEJMoa1902328","journal-title":"N Engl J Med"},{"issue":"21","key":"4376_CR118","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1182\/blood.2020009984","volume":"138","author":"D R\u00e9a","year":"2021","unstructured":"R\u00e9a D, Mauro MJ, Boquimpani C et al (2021) A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood 138(21):2031\u20132041. https:\/\/doi.org\/10.1182\/blood.2020009984","journal-title":"Blood"},{"key":"4376_CR119","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2020.106458","volume":"98","author":"PW Manley","year":"2020","unstructured":"Manley PW, Barys L, Cowan-Jacob SW (2020) The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase. Leuk Res 98:106458. https:\/\/doi.org\/10.1016\/j.leukres.2020.106458","journal-title":"Leuk Res"},{"key":"4376_CR120","doi-asserted-by":"publisher","first-page":"8120","DOI":"10.1021\/acs.jmedchem.8b01040","volume":"61","author":"J Schoepfer","year":"2018","unstructured":"Schoepfer J, Jahnke W, Berellini G et al (2018) Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1. J Med Chem 61:8120\u20138135. https:\/\/doi.org\/10.1021\/acs.jmedchem.8b01040","journal-title":"J Med Chem"},{"issue":"17","key":"4376_CR121","doi-asserted-by":"publisher","first-page":"13423","DOI":"10.18632\/oncotarget.24393","volume":"9","author":"LN Eadie","year":"2018","unstructured":"Eadie LN, Saunders VA, Branford S et al (2018) The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro. Oncotarget 9(17):13423. https:\/\/doi.org\/10.18632\/oncotarget.24393","journal-title":"Oncotarget"},{"key":"4376_CR122","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2021.1941863","author":"M Breccia","year":"2021","unstructured":"Breccia M, Colafigli G, Scalzulli E, Martelli M (2021) Asciminib: an investigational agent for the treatment of chronic myeloid leukemia. Expert Opin Investig Drugs. https:\/\/doi.org\/10.1080\/13543784.2021.1941863","journal-title":"Expert Opin Investig Drugs"},{"issue":"2","key":"4376_CR123","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-021-00420-8","volume":"11","author":"V Garcia-Guti\u00e9rrez","year":"2021","unstructured":"Garcia-Guti\u00e9rrez V, Luna A, Alonso-Dominguez JM et al (2021) Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice. Blood Cancer J 11(2):1\u20134. https:\/\/doi.org\/10.1038\/s41408-021-00420-8","journal-title":"Blood Cancer J"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-022-04376-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11010-022-04376-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-022-04376-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T06:16:10Z","timestamp":1646892970000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11010-022-04376-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,7]]},"references-count":123,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["4376"],"URL":"https:\/\/doi.org\/10.1007\/s11010-022-04376-6","relation":{},"ISSN":["0300-8177","1573-4919"],"issn-type":[{"value":"0300-8177","type":"print"},{"value":"1573-4919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,7]]},"assertion":[{"value":"24 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this type of study, formal consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}